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Abstract
High levels of choline kinase (ChoK) expression and choline phospholipid metabolites are often associated with
malignant transformation, invasion, and metastasis, particularly in breast cancer. These findings have led to the
development of novel pharmacologic or gene therapeutic interventions for ChoK-targeted inhibition. To identify
pharmacodynamic markers for the therapeutic evaluation of ChoK down-regulation, we investigated the uptake
and efflux of [3H]choline, a natural substrate of ChoK, and two other important metabolic indicators of malignancy,
namely, [3H]thymidine and [3H]fluorodeoxyglucose, which measure proliferation and glucose metabolic changes,
respectively, in ChoK-downregulated cells. Choline uptake in nonmalignant and malignant breast epithelial cell
lines expressing graded levels of ChoK showed a ChoK-dependent uptake, retention, and efflux of [3H]choline. Re-
duced proliferation observed because of ChoK down-regulation resulted in reduced [3H]thymidine uptake and incor-
poration into DNA within 48 hours of treatment. Reduced [3H]thymidine incorporation levels were consistent with a
decreased cell cycle S-phase fraction. No change in [3H]fluorodeoxyglucose uptake was observed between ChoK-
downregulated and control cells in any of the three cell lines tested. These results demonstrate the utility of radio-
labeled choline or choline analogs and proliferation imaging agents as pharmacodynamic markers for ChoK-targeted
therapies and suggest a ChoK-mediated mechanism for tumor sequestration of choline-based imaging agents.
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Introduction
Elevated levels of total choline primarily due to an increase in choline
metabolites such as phosphocholine (PC) have been detected in several
cancers, including breast [1,2], prostate [3], colon [4], and brain [5],
using magnetic resonance (MR) spectroscopy. Human breast cancer
cells and tumors, especially, exhibit consistently elevated levels of
PC [6,7], allowing total choline levels to be used to discriminate be-
tween malignant and benign lesions [8]. In addition, progressively
elevated levels of total choline and PC were observed in immortalized,
oncogene-transformed, and tumor-derived breast epithelial cells [9].
Decreased tumor total choline levels are usually associated with a posi-
tive response to conventional chemotherapy in breast cancer [10] and
suggest a role for choline compounds as biomarkers to assess response
to chemotherapy.
Phosphocholine, which is formed by the phosphorylation of free
choline by choline kinase (ChoK), is a precursor as well as a break-
down product of phosphatidylcholine (PtdCho), the major phospho-
lipid constituent of cell membranes. Formation of PC depends on
choline transport, ChoK expression and activity, and phospholipase
expression levels and activities [11–13]. There is increasing evidence
that phosphorylation of choline by ChoK can regulate PtdCho bio-
synthesis [14,15]. Increased PC and PtdCho levels accompany an
increase in ChoK activity or expression, suggesting a critical role for
ChoK in malignant transformation [11,13,16,17]. Overexpression
and increased activity of ChoK as well as associated PC levels were
reported in breast, lung, prostate, and colon cancer cell lines and in
breast and colon tumors [16,18–21]. The increased ChoK activity
in tumor-derived cell lines and human tumors compared with their
corresponding normal tissues supports a role for ChoK in malignant
transformation [16,22]. Two genes, namely, ChoK-α and ChoK-β, code
for the two gene products ChoK-α and ChoK-β. ChoK-α exists as two
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isoforms, ChoK-α1 (50 kDa, 435 amino acids) and ChoK-α2 (52 kDa,
453 amino acids), which are highly homologous and derived from
the identical gene ChoK-α by alternative splicing. ChoK-β is a sepa-
rate gene product formed from ChoK-β [23]. Recently, overexpression
of ChoK-α has been implicated as a predictive marker of recurrence
in lung cancer [24]. These findings suggest ChoK as a potential thera-
peutic target for pharmacologic or gene therapeutic interventions. Bis-
quaternery compounds based on hemicholimium 3 as inhibitors of
ChoK and ChoK-specific small interfering RNA (siRNA) technology
are being actively pursued to target ChoK [25–27]. Also, combination
treatments that include ChoK-α down-regulation in association with
antineoplastic agents such as 5-fluorouracil have been tested. In a recent
study, Mori et al. [28] demonstrated that down-regulation of ChoK
increased the effect of 5-fluorouracil treatment in breast cancer cells,
suggesting that ChoK may represent a novel target to enhance the effec-
tiveness of anticancer agents.
The recent shift in anticancer therapeutics from conventional cyto-
toxic compounds to targeted agents, which may be cytostatic, requires
novel measures of monitoring that are able to replace traditional end
points such as tumor shrinkage or survival. Surrogate end points that
use imaging are particularly desirable to detect early, physiologic changes
in the tumor and enable switching from ineffective therapies in real
time. Accordingly, there is a great need to develop molecular imaging
techniques and suitable pharmacodynamic markers in conjunction with
molecular therapeutics. Positron emission tomography (PET) and MR
methods are two clinically translatable, noninvasive imaging techniques
that are increasingly being used to detect tumor response to targeted
therapy [29,30]. Significant progress has been made in using non-
invasive MR-based techniques to assess the total choline signal in
tumors as a measure of ChoK treatment response [27,31]. Here,
we have used [3H]choline, a natural substrate of ChoK, and two
other clinically important metabolic indicators of malignancy, namely,
[3H]fluorodeoxyglucose ([3H]FDG) for glucose metabolism and
[3H]thymidine ([3H]Tdr) for proliferation, to detect ChoK activity
andChoK targeting in breast cancer cells.We observedChoK-dependent
uptake and retention of [3H]choline in these cells. In addition, re-
duced proliferation due to siRNA-mediated ChoK down-regulation
was detected as early as 48 hours after initiation of treatment. These
studies support the use of radiolabeled choline or choline analogs and
proliferation imaging agents as noninvasive markers for in vivo evalua-
tion of ChoK-targeted therapy using PET-based nuclear imaging.
Materials and Methods
Radiochemicals
[3H]Choline chloride (83.0 Ci/mmol, >99% radiochemical purity),
[3H]Tdr (63.8 Ci/mmol, >99% radiochemical purity), and [3H]FDG
(60.0 Ci/mmol, >99% radiochemical purity) were obtained from
Amersham Biosciences (Piscataway, NJ), Moravek Biochemicals (Brea,
CA) and American Radiochemicals, Inc (St. Louis, MO), respectively.
Cell Lines
An immortalized human mammary epithelial cell line MCF-12A,
and the estrogen receptor (ER)/progesterone receptor (PR)–positive
MCF-7 and the ER/PR–negative MDA-MB-231 human breast cancer
cell lines, with progressively increasing levels of ChoK expression and
malignancy, were used for the studies. All cell lines were purchased
from American Type Culture Collection (Rockville, MD) and were
maintained as described previously [27].
Determination of Protein Content and Western Blot Analysis
Cells were washed twice with PBS and homogenized with TB
buffer (100 mM Tris (pH 6.7), 2% SDS, 12% glycerol) containing
protease inhibitor cocktail (Sigma, St. Louis, MO). Protein concentra-
tions were determined using a Biorad (Hercules, CA) protein assay kit.
Standard concentrations of bovine serum albumin were used to obtain
a calibration curve. Aliquots containing 20 μg of the total protein along
with a molecular weight standard were loaded and electrophoretically
separated on a 10% polyacrylamide gel. Separated proteins were trans-
ferred onto nitrocellulose membranes and blocked with 5% nonfat
milk with 0.05% Tween-20 overnight at 4°C. Membranes were then
incubated with custom-made rabbit polyclonal ChoK-α–specific pri-
mary antibody (immunoglobulin G, 1:100 dilution) raised against a
hydrophilic synthetic peptide (Proteintech Group, Inc, Chicago, IL)
[27] followed by goat antirabbit antibody conjugated to horseradish
peroxidase (1:10,000 dilution). After three washes bands were visual-
ized using Supersignal West Pico chemiluminescent substrate kit (Pierce
Biotechnology, Rockford, IL) [27].
Cell Transfections and General Procedure for
Radiopharmaceutical Uptake Studies
All three cell lines were seeded at 1 × 105 cell/ml in six-well plates.
Approximately 30% to 50% confluent cells were transiently trans-
fected with 2.6 nmol of the ChoK-specific siRNA (ChoK-siRNA;
Dharmacon, Lafayette, CO) using Oligofectamine (Invitrogen, San
Diego, CA) according to the manufacturer’s instructions. Control cells
were treated with Oligofectamine alone. After 48 hours of transfection,
cells were washed twice and incubated with the appropriate radiophar-
maceutical for different periods. Any changes from this general procedure
are mentioned in the appropriate section discussed later. Radioactivity
concentrations were determined by mixing supernatants or solubilized
pellets with 10 to 15 ml of Ultima Gold scintillation cocktail (Packard
Bioscience, Meriden, CT), which was counted for 5 minutes on a liquid
scintillation counter (Tri-Carb; Packard Bioscience) with external stan-
dard quench correction. All experiments were performed in triplicate,
with data reported as percentage of incubated dose (%ID) per micro-
gram of total protein.
[3H]Choline Uptake
Transfected cell lines and their controls were incubated with
[3H]choline chloride at 0.2 μCi/well for 5, 15, 30, 45, 60, 120,
and 180 minutes. At the end of the incubation period, cells were
rinsed four times with ice-cold PBS, and the cell pellet was solubilized
using 0.2 ml of Solvable (Packard Bioscience). Radioactivity concen-
trations were determined as described above.
[3H]Choline Efflux
Transfected cell lines and their controls were pulsed with 0.2 μCi/
well of [3H]choline chloride for 10 minutes. Then, after aspiration of
the radioactive medium, cells were rinsed twice with ice-cold PBS, re-
freshed with 2 ml of standard medium, and transferred into a 37°C
incubator. No cold choline was added during the experiment. Previous
studies determined that medium used in these studies contained
20 μM of choline [11]. Effluxed activity was measured by counting
radioactivity in the medium at 15, 30, 45, 60, 120, and 180 minutes.
[3H]Thymidine Uptake
Transfected cell lines and their controls were incubated with [3H]Tdr
at 0.2 μCi/well for 5, 15, 30, 45, 60, 120, and 180 minutes. After the
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designated incubation period, cells were washed three times with
ice-cold PBS, trypsinized, and extracted with 1 M perchloric acid.
Total radioactivity in the soluble fraction and radioactivity in the
DNA pellet, after solubilization with Solvable (Perkin-Elmer Life
Sciences, Waltham, MA), were measured in a scintillation counter
as described above.
S-Phase Analysis
For bromodeoxyuridine (BrdU) staining, cells were incubated with
10 μM BrdU for 45 minutes at 48 hours after transfection. Cells
were harvested, pelleted, washed with PBS containing 1% bovine
serum albumin, resuspended in 100 μl of PBS, and fixed in 4 ml
of chilled 70% ethanol. Before staining, cells were pelleted at 300g
for 5 minutes and incubated in 0.5 ml of a solution containing 2 M
HCl for 30 minutes at room temperature. The acid was then neutral-
ized with 0.5 ml of 0.1 M sodium tetraborate (pH 8.5). Cells were
pelleted, washed once with PBS buffer, and incubated in 100 μl of
PBS buffer containing 20 μl of fluorescein isothiocyanate–conjugated
anti-BrdU antibody for 30 minutes at ambient temperature. After
antibody incubation, cells were washed once with PBS buffer and
then incubated in 0.5 ml of PBS containing 20 μl/ml of propidium
iodide (PI) and 40 μl/ml of RNAse. Cells were then analyzed on BD
FACScan (BD Biosciences, San Jose, CA) to determine PI (red) and
fluorescein isothiocyanate (green) staining for nuclear DNA and
BrdU content, respectively.
[3H]Fluorodeoxyglucose Uptake
One hour before [3H]FDG incubation, transfected MDA-MB-231
cells and MCF-12A cells were incubated with low-glucose (1.0 g/L)
medium to mimic plasma concentration levels. MCF-7 cells were in-
cubated with [3H]FDG without any modification in the minimum
essential medium. Transfected cell lines and their controls, incubated
with 0.2 μCi/well of [3H]FDG for variable periods, were processed
as described in the general procedure.
Statistical Analysis
Statistical analysis was performed using prism software (La Jolla,
CA) using an unpaired, 2-tailed t test. P values <.05 for the compar-
ison between ChoK-downregulated cells and the corresponding con-
trols were considered to be significant.
Results
Choline Kinase Down-regulation
Choline kinase expression levels increased with increasing malig-
nancy of the cell lines, i.e., MDA-MB-231 > MCF-7 > MCF-12A
(Figure 1). Using ChoK-specific siRNA, we were able to achieve 40%
to 60% ChoK-α down-regulation compared with Oligofectamine-
treated control, consistent with previously published reports [27,28]
(Figure 1).
[3H]Choline Uptake
The accumulation of choline compounds in cancer cells is a func-
tion of both choline transport and rapid phosphorylation by ChoK.
To investigate the importance of ChoK, we incubated the two malig-
nant cell lines, MDA-MB-231 and MCF-7, and the nonmalignant,
immortalized human mammary epithelial cell line, MCF-12A, with
[3H]choline for various periods. Down-regulation of ChoK in high
ChoK-expressing cells resulted in a significant reduction in [3H]choline
accumulation–related radioactivity with time, which was not observed
in the nonmalignant epithelial cell line with low ChoK expression (Fig-
ure 2). Oligofectamine treatment alone did not result in any statistically
significant difference in [3H]choline uptake compared with untreated
cells in all the three cell lines, hence Oligofectamine-treated cells were
used as controls for all comparisons. In the cancer cell lines, ChoK-
siRNA treatment resulted in a significant decrease in [3H]choline up-
take and accumulation from the 45-minute incubation period onward
(P < .001). To facilitate comparison with clinical studies, where carbon-
11– or fluorine-18–labeled analogs are used, all of our in vitro data were
compared at the 60-minute time point typically used for clinical studies.
At 60 minutes, ChoK down-regulation resulted in 42% (P < .0001),
38% (P < .0001), and 18% (P < .0175) reductions in overall choline
uptake in MDA-MB-231, MCF-7, and MCF-12A cells, respectively,
compared with controls.
[3H]Choline Efflux and Retention
To investigate whether the reduced accumulation of radioactivity
observed was due to lack of ChoK-mediated phosphorylation of
free choline, we pulsed all of the three cell lines with [3H]choline
for 10 minutes. After exchanging the labeled medium with the un-
labeled medium, the effluxed radioactivity was collected from the
medium at various time points after the pulse. In all three ChoK-
downregulated cell lines, the maximum efflux of radioactivity was
observed within 15 minutes (Figure 3). After 15 minutes, efflux of
radioactivity was either only slightly higher or remained the same as
that observed at 15 minutes. Among the three cell lines, the highest
efflux of radioactivity was detected in the MCF-12A cell line, which
had the lowest ChoK expression levels. The efflux of radioactivity in
ChoK-downregulated cell lines was 40% (P < .0001), 58% (P <
.0001), and 7% (P = .5701) higher in MDA-MB-231, MCF-7,
and MCF-12A cell lines, respectively, at 60 minutes compared with
Oligofectamine-treated controls.
The radioactivity retained after the efflux experiments (Figure 4) sup-
ports the results obtained from the efflux experiments. There was no
significant difference in radioactivity retained between Oligofectamine-
treated and ChoK-downregulated MCF-12A cells, whereas both cancer
cell lines treated with ChoK-siRNA showed less retention of radio-
activity than control cells.
[3H]Thymidine Uptake, DNA Incorporation, and
S-Phase Analysis
Choline kinase and choline-related metabolites are involved in pro-
liferation [32]. Although the relationship between ChoK and the cell
cycle and DNA synthesis is not completely characterized, recent re-
ports suggest that ChoK plays a role in regulating G1 to S transition
Figure 1. Choline kinase down-regulation in MDA-MB-231, MCF-7,
and MCF-12A breast cancer cell lines as detected by ChoK-α–
specific antibody.
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and thereby proliferation [32,33]. To understand further the role of
ChoK in cell proliferation, we used [3H]Tdr, an analog of an imaging
agent that reports on proliferation. Both the cancer cell lines showed
statistically significant and consistently reduced [3H]Tdr uptake and
DNA incorporation (Figures 5 and 6) after treatment with ChoK-
siRNA. The changes in [3H]Tdr uptake and DNA incorporation were
significant at 60 minutes. In the MCF-12A cell line, although the thy-
midine uptake was not statistically significant at 60 minutes, a signifi-
cant change (P < .05) in DNA incorporation was observed. Choline
kinase–downregulated MDA-MB-231, MCF-7, and MCF-12A cells
showed 62%, 51%, and 44% lower [3H]Tdr uptake than the
corresponding Oligofectamine-treated cells at 60 minutes (Figure 5).
Similarly at 60 minutes, the percentage of DNA incorporation was re-
duced by 67% (P < .005), 54% (P < .018), and 32% (P = .013), re-
spectively (Figure 6). To confirm that the [3H]Tdr uptake and DNA
incorporation values reflected changes in S-phase fraction, we correlated
these results with BrdU incorporation and PI staining for S-phase
fraction analysis by flow cytometry. Whereas the cancer cell lines show
a significant difference in S-phase fraction after treatment, in the non-
malignant breast epithelial cell line, the difference was not significant
(Figure 7).
[3H]Fluorodeoxyglucose Uptake
To determine whether FDG-PET could eventually be used as a
surrogate marker for ChoK activity, we investigated changes in glu-
cose metabolism using [3H]FDG uptake. The absolute accumulation
Figure 3. Efflux of [3H]choline chloride depends on ChoK expression levels. MDA-MB-231, MCF-7, and MCF-12A breast cancer cell lines
were untreated (clear bar), treated with Oligofectamine alone (gray bar), or transfected with ChoK-specific siRNA (solid black bar). At
48 hours after transfection, cells were pulsed with 0.2 μCi/ml of [3H]choline chloride for 10 minutes. After the replacement of radioactive
medium and refreshing with fresh medium, cells were incubated for variable periods. At the specified time, supernatant radioactivity
was counted and represented as %ID per microgram of total protein. Results shown are the mean values of experiments performed in
triplicate and from three independent experiments. The significance of the value is indicated by asterisks (*), and the comparative refer-
ence is the corresponding cell line treated with Oligofectamine alone. ns indicates nonsignificant. *P < .05, **P < .01, ***P < .001.
Figure 2. Kinetics of [3H]choline uptake in MDA-MB-231, MCF-7, and MCF-12A breast cancer cell lines with varying levels of ChoK
expression. Cell lines were untreated (clear bar), treated with Oligofectamine alone (gray bar), or transfected with ChoK-specific siRNA
(solid black bar) and, at 48 hours after transfection, were incubated with 0.2 μCi/ml of [3H]choline chloride for increasing periods. Results
shown are the mean values of experiments performed in triplicate and from three independent experiments. Results are represented as
%ID per microgram of total protein. The significance of the value is indicated by asterisks (*), and the comparative reference is the
corresponding cell line treated with Oligofectamine alone. ns indicates nonsignificant. *P < .05, **P < .01, ***P < .001.
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of [3H]FDG uptake varied with the cell line with malignant cells
demonstrating higher accumulation of radioactivity compared with
nonmalignant MCF-12A cells (Figure 8). However, there were no
significant differences in [3H]FDG uptake between Oligofectamine-
treated control and ChoK-downregulated cells in any of the three
cell lines.
Discussion
The purposes of this study were to 1) delineate the role of ChoK
in the uptake of radiolabeled choline and retention of radiolabeled
choline metabolites, 2) assess the feasibility of monitoring the
ChoK-targeted therapies using radiolabeled choline analogs, and 3)
assess the feasibility of monitoring the ChoK-targeted therapies using
other downstream pharmacodynamic markers. To investigate these
hypotheses, we downregulated ChoK using siRNA targeted against
both the ChoK-α and ChoK-β isoforms using previously established
methods [27,28]. Using Oligofectamine-treated controls and ChoK-
downregulated cell lines, we characterized choline uptake and reten-
tion in nonmalignant MCF-12A cells and malignant MCF-7 and
MDA-MB-231 cells. The accumulated or effluxed radioactivity was
normalized to the percentage of incubated dose as well as micro-
grams of total protein. Because different cell lines may have different
total protein concentration, comparisons were made within and not
between cell lines after ChoK-siRNA treatment. Our experiments
Figure 5. Total [3H]Tdr uptake is indicative of reduced proliferation in ChoK-downregulated breast cancer cells. MDA-MB-231, MCF-7,
and MCF-12A breast cancer cell lines were untreated (clear bar), treated with Oligofectamine alone (gray bar), or transfected with ChoK-
specific siRNA (solid black bar). At 48 hours after transfection, cells were incubated with 0.2 μCi/ml of [3H]Tdr for variable periods. At
the specified interval, total [3H]Tdr uptake was measured and represented as %ID per microgram of total protein. Results shown
are the mean values of experiments performed in triplicate and from three independent experiments. The significance of the value
is indicated by asterisks (*), and the comparative reference is the corresponding cell line treated with Oligofectamine alone. ns indicates
nonsignificant. *P < .05, **P < .01, ***P < .001.
Figure 4. Retention of [3H]choline chloride is ChoK-dependent. MDA-MB-231, MCF-7, and MCF-12A breast cancer cell lines were
untreated (clear bar), treated with Oligofectamine alone (gray bar), or transfected with ChoK-specific siRNA (solid black bar). At
48 hours after transfection, cells were pulsed with 0.2 μCi/ml of [3H]choline chloride for 10 minutes. After the replacement of radioactive
medium and refreshing with fresh medium, cells were incubated for variable periods. At the specified time, supernatant radioactivity
was removed, and the cell-associated radioactivity was counted and represented as %ID per microgram of total protein. Results shown
are the mean values of experiments performed in triplicate and from three independent experiments. The significance of the value
is indicated by asterisks (*), and the comparative reference is the corresponding cell line treated with Oligofectamine alone. ns indicates
nonsignificant. *P < .05, **P < .01, ***P < .001.
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revealed ChoK-dependent uptake and retention of radioactivity in
all three cells lines. The uptake of radiolabeled choline in cancer
cell lines with high ChoK expression levels was 35% to 40% higher
than that in the nonmalignant cell line. This is consistent with the
progressively increased levels of PC and total choline–containing
compounds detected with MR spectroscopy studies in these cell lines
[27]. In addition, down-regulation of ChoK using siRNA technology
resulted in low uptake and retention of radiolabeled choline in ma-
lignant cells in a time-dependent manner, whereas the uptake and
retention in a nonmalignant cell line remained statistically insignifi-
cant. Furthermore, the increased efflux of radioactivity observed in
ChoK-downregulated cancer cell lines indicates the presence of un-
phosphorylated free choline. Both the reduced retention and in-
creased efflux of [3H]choline in ChoK-downregulated cancer cell
lines clearly underline the importance of ChoK in the phosphoryla-
tion and subsequent intracellular retention of radiolabeled choline
metabolites. Overall, these data suggest that reduced uptake and re-
tention of radiolabeled choline is due to the downregulated ChoK
levels, making it a suitable imaging marker for monitoring ChoK-
targeted therapies.
To investigate other pharmacodynamic markers for noninvasive
monitoring of ChoK-based therapies, we also investigated [3H]Tdr,
a marker for proliferation, and [3H]FDG, a marker for glucose me-
tabolism. Previous studies targeting ChoK inhibition using either
siRNA knockdown or pharmacological inhibition resulted in reduced
cellular proliferation [25–27,31]. The de novo reduction in PC
synthesis due to ChoK inhibition has been attributed to G1- to
S-phase arrest [32,33]. To measure proliferation changes as a result
of ChoK-targeted therapy, we assessed the uptake and retention of
[3H]Tdr. Our in vitro results show a significant reduction in total
[3H]Tdr uptake and DNA incorporation in cancer cell lines after ChoK
silencing and are in agreement with previous studies [27,31]. The
proliferation levels in the nonmalignant MCF-12A cell line were af-
fected but not significantly. These results suggest that monitoring
ChoK-targeted treatment using a proliferation-based imaging agent
Figure 7. Reduced [3H]Tdr is due to the low S-phase fraction in
ChoK downregulated breast cancer cells. MDA-MB-231 (clear bar),
MCF-7 (gray bar), and MCF-12A (solid black bar) breast cancer cell
lines were untreated, treated with Oligofectamine alone, or trans-
fected with ChoK-specific siRNA. At 48 hours after transfection, cells
were incubated with BrdU for 45 minutes and analyzed by flow
cytometry after S-phase fraction staining with anti-BrdU and DNA
staining with PI as indicated in the Materials and Methods section.
Results shown are the mean values of single experiment performed
in triplicate and from three independent experiments. The signifi-
cance of the value is indicated by asterisks (*), and the comparative
reference is the corresponding cell line treated with Oligofectamine
alone. ns indicates nonsignificant. *P< .05, **P< .01, ***P< .001.
Figure 6. [3H]Thymidine DNA incorporation is reduced in ChoK-downregulated breast cancer cells. MDA-MB-231, MCF-7, and MCF-12A
breast cancer cell lines were untreated (clear bar), treated with Oligofectamine alone (gray bar), or transfected with ChoK-specific siRNA
(solid black bar). At 48 hours after transfection, cells were incubated with 0.2 μCi/ml of [3H]Tdr for variable periods. At specified intervals,
[3H]Tdr incorporation into DNA was assessed using perchloric acid extraction and represented as %ID per microgram of total protein.
Results shown are the mean values of experiments performed in triplicate and from three independent experiments. The significance of
the value is indicated by asterisks (*), and the comparative reference is the corresponding cell line treated with Oligofectamine alone. ns
indicates nonsignificant. *P < .05, **P < .01, ***P < .001.
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may be possible. Although a radiolabeled version of Tdr would be
an ideal radiopharmaceutical for monitoring proliferation, the use of
[11C]Tdr is fraught by rapid metabolism in vivo [34]. 3′-Deoxy-3′-
[18F]-fluorothymidine ([18F]FLT) is currently being pursued as an
alternative to [11C]Tdr [35]. It is taken up in cells, phosphorylated,
and trapped by cytosolic Tdr kinase. Cytosolic thymidine kinase
(TK1) levels correlate directly with S-phase fraction [36]. Hence,
FLT-PET is being used as an imaging-based biomarker for detection
and monitoring of early changes in cancer chemotherapy [37,38].
Although [18F]FLT is an accepted marker for cell proliferation, it is
not an indicator of DNA synthesis. To monitor the changes in reduced
DNA synthesis as a result of ChoK-based therapies, one could use
imaging agents that are incorporated into DNA for protracted studies
[39,40]. Our results support the use of both TK-based as well as DNA
synthesis–based imaging agents for monitoring ChoK-targeted thera-
pies. Although these studies demonstrate feasibility, additional studies
are needed to correlate further the proliferation changes induced by
ChoK inhibition with proliferation-based imaging agents.
Malignant cells exhibit increased use of glucose, and many cancers
are known to overexpress glucose transporters, including glucose
transporter 1 and hexokinase, which allow rapid use of glucose
[41,42]. The use of [18F]FDG in cancer imaging is based on in-
creased glucose metabolism in tumors [43,44]. [18F]Fluorodeoxyglu-
cose is by far the most commonly used radiopharmaceutical for the
diagnosis, detection, and therapeutic management of cancer [45]. Pre-
viously, attempts were made to correlate FDG metabolism with phos-
pholipid synthesis [46,47]. However, there are no current reports on
the effect of ChoK down-regulation on glucose metabolism in cancer
cells. Herein, we observed increased [3H]FDG uptake in both cancer
cell lines compared with the nonmalignant MCF-12A cell line. How-
ever, no significant changes in glucose metabolism, using [3H]FDG
could be detected either in malignant or nonmalignant cell lines be-
tween ChoK-downregulated and control cells. These results suggest
that glucose metabolism may not be a suitable option for noninvasive
monitoring of ChoK-based therapies.
In conclusion, our study demonstrates that radiolabeled choline or
choline analogs can be used to detect the effects of ChoK-targeted
therapy. Other pharmacodynamic markers such as proliferation im-
aging with [11C]Tdr or [18F]FLTmay provide alternatives for repetitive
and noninvasive monitoring of ChoK inhibition. In addition, other
routinely used metabolic imaging agents such as [18F]FDG may not
be useful to detect the early changes of ChoK-based therapies.
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